Author details

Full Name

Hartmut Land

Affiliation

University of Rochester Medical Center, Wilmot Cancer Institute

ORCID

Career Start Year

1974

Papers

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
36044839	Arid1a mutation suppresses TGF-Î² signaling and induces cholangiocarcinoma.	Cell Rep	2022
36181678	Protocol to use TopNet for gene regulatory network modeling using gene expression data from perturbation experiments.	STAR Protoc	2022
34936873	Gene network modeling via TopNet reveals functional dependencies between diverse tumor-critical mediator genes.	Cell Rep	2021
33243147	Multiple imputation and direct estimation for qPCR data with non-detects.	BMC Bioinformatics	2020
27966447	A four gene signature predictive of recurrent prostate cancer.	Oncotarget	2017
27732857	Addiction to Coupling of the Warburg Effect with Glutamine Catabolism in Cancer Cells.	Cell Rep	2016
26142707	Inhibition of COP9-signalosome (CSN) deneddylating activity and tumor growth of diffuse large B-cell lymphomas by doxycycline.	Oncotarget	2015
24764462	On non-detects in qPCR data.	Bioinformatics	2014
24794439	Plac8 links oncogenic mutations to regulation of autophagy and is critical to pancreatic cancer progression.	Cell Rep	2014
23077212	The Birt-Hogg-DubÃ© tumor suppressor Folliculin negatively regulates ribosomal RNA synthesis.	Hum Mol Genet	2013
23733954	Unphosphorylated STAT5A stabilizes heterochromatin and suppresses tumor growth.	Proc Natl Acad Sci U S A	2013
22964631	Gene signature critical to cancer phenotype as a paradigm for anticancer drug discovery.	Oncogene	2013
22266220	Kras(G12D) and p53 mutation cause primary intrahepatic cholangiocarcinoma.	Cancer Res	2012
22981231	Anticancer activity of the cholesterol exporter ABCA1 gene.	Cell Rep	2012
22863534	Gene sets identified with oncogene cooperativity analysis regulate in vivo growth and survival of leukemia stem cells.	Cell Stem Cell	2012
23089817	Fitting Boolean networks from steady state perturbation data.	Stat Appl Genet Mol Biol	2011
18500333	Synergistic response to oncogenic mutations defines gene class critical to cancer phenotype.	Nature	2008
17310253	Tumor suppressor p53 restricts Ras stimulation of RhoA and cancer cell motility.	Nat Struct Mol Biol	2007
11781841	Recruitment of TRRAP required for oncogenic transformation by E1A.	Oncogene	2001
11258707	p19ARF-independent induction of p53 and cell cycle arrest by Raf in murine keratinocytes.	EMBO Rep	2001
10508164	Cyclins D1 and D2 mediate myc-induced proliferation via sequestration of p27(Kip1) and p21(Cip1).	EMBO J	1999
9188852	Myc activation of cyclin E/Cdk2 kinase involves induction of cyclin E gene transcription and inhibition of p27(Kip1) binding to newly formed complexes.	Oncogene	1997
9271434	High-intensity Raf signal causes cell cycle arrest mediated by p21Cip1.	Mol Cell Biol	1997
9119230	Cooperating oncogenes converge to regulate cyclin/cdk complexes.	Genes Dev	1997
8840976	Immortalization and transformation are associated with specific alterations in choline metabolism.	Cancer Res	1996
7478619	Expression of cyclin D1 mRNA is not upregulated by Myc in rat fibroblasts.	Oncogene	1995
8531699	Transformation of primary rat embryo cells.	Methods Enzymol	1995
7846125	Integrated control of cell proliferation and cell death by the c-myc oncogene.	Philos Trans R Soc Lond B Biol Sci	1994
8193530	Myc-Max-Mad: a transcription factor network controlling cell cycle progression, differentiation and death.	Curr Opin Genet Dev	1994
8425220	Oncogenic activity of the c-Myc protein requires dimerization with Max.	Cell	1993
8265351	Distinct DNA binding preferences for the c-Myc/Max and Max/Max dimers.	Nucleic Acids Res	1993
8262051	The c-Myc protein induces cell cycle progression and apoptosis through dimerization with Max.	EMBO J	1993
1406955	Transcriptional activation by the human c-Myc oncoprotein in yeast requires interaction with Max.	Nature	1992
1555236	Induction of apoptosis in fibroblasts by c-myc protein.	Cell	1992
1501888	Max and c-Myc/Max DNA-binding activities in cell extracts.	Oncogene	1992
21416356	Choice and manipulation of retroviral vectors.	Methods Mol Biol	1991
1694289	Establishment of rat endometrial cell lines by retroviral mediated transfer of immortalizing and transforming oncogenes.	Oncogene	1990
2182320	Negative autoregulation of c-myc transcription.	EMBO J	1990
2156225	A series of mammalian expression vectors and characterisation of their expression of a reporter gene in stably and transiently transfected cells.	Nucleic Acids Res	1990
2133113	C-MYC: evidence for multiple regulatory functions.	Semin Cancer Biol	1990
2201910	Domains of human c-myc protein required for autosuppression and cooperation with ras oncogenes are overlapping.	Mol Cell Biol	1990
2201028	Cooperation between two growth factors promotes extended self-renewal and inhibits differentiation of oligodendrocyte-type-2 astrocyte (O-2A) progenitor cells.	Proc Natl Acad Sci U S A	1990
2373025	Control of division and differentiation in oligodendrocyte-type-2 astrocyte progenitor cells.	Ciba Found Symp	1990
2194165	Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line.	Nucleic Acids Res	1990
1708633	[Induction of primitive neuroectodermal tumors by oncogene complementation].	Verh Dtsch Ges Pathol	1990
2538247	Multistage carcinogenesis induced by ras and myc oncogenes in a reconstituted organ.	Cell	1989
2483370	An in situ transgenic enzyme marker for the midgestation mouse embryo and the visualization of inner cell mass clones during early organogenesis.	Development	1989
2557356	Transforming growth factors-beta 1 and beta 2 are mitogens for rat Schwann cells.	J Cell Biol	1989
2648394	The ras and myc oncogenes cooperate in tumor induction in many tissues when introduced into midgestation mouse embryos by retroviral vectors.	Proc Natl Acad Sci U S A	1989
3049071	Ras-mediated cell cycle arrest is altered by nuclear oncogenes to induce Schwann cell transformation.	EMBO J	1988

1 - 50 of 70

Michael A White

University of Georgia

Career Start Year 1994

Number of shared co-authors 1

Celio Pouponnot

Institut Curie

Career Start Year 1993

Number of shared co-authors 0

Sanja Pajovic

Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children

Career Start Year 1993

Number of shared co-authors 0

William Clark

Cancer Research UK Beatson Institute

Career Start Year 1993

Number of shared co-authors 0

Stephen Chung

Princess Margaret Cancer Centre, University Health Network

Career Start Year 1993

Number of shared co-authors 0

Andrei Goga

University of California San Francisco

Career Start Year 1993

Number of shared co-authors 0

Rosalie C Sears

Oregon Health and Science University

Career Start Year 1987

Number of shared co-authors 0

Claudio Schneider

Laboratorio Nazionale-Consorzio Interuniversitario per le Biotecnologie

Career Start Year 1987

Number of shared co-authors 0

William C Hahn

Broad Institute of MIT and Harvard, USA Dana-Farber Cancer Institute

Career Start Year 1987

Number of shared co-authors 3

Colin R Goding

Ludwig Institute for Cancer Research, University of Oxford

Career Start Year 1983

Number of shared co-authors 0

Edison T Liu

USA The Jackson Laboratory Cancer Center

Career Start Year 1982

Number of shared co-authors 0

Tom Curran

Medical University of South Carolina

Career Start Year 1982

Number of shared co-authors 0

Parmjit S Jat

UCL Institute of Prion Diseases

Career Start Year 1981

Number of shared co-authors 5

Ze'ev Ronai

Cancer Center, Sanford Burnham Prebys Medical Discovery Institute

Career Start Year 1981

Number of shared co-authors 0

David M Thomas

Garvan Institute of Medical Research

Career Start Year 1980

Number of shared co-authors 0

Dirk Eick

Helmholtz Center Munich and Center for Integrated Protein Science Munich (CIPSM)

Career Start Year 1980

Number of shared co-authors 0

Alexander Kamb

Inc. 30301 Agoura Rd.

Career Start Year 1979

Number of shared co-authors 0

Michael C Ostrowski

Hollings Cancer Center, Medical University of South Carolina

Career Start Year 1979

Number of shared co-authors 0

Colin S Cooper

Norwich Medical School, University of East Anglia

Career Start Year 1978

Number of shared co-authors 0

Glenn Merlino

Center for Cancer Research, National Cancer Institute, National Institutes of Health

Career Start Year 1978

Number of shared co-authors 1

Chi V Dang

Johns Hopkins University School of Medicine

Career Start Year 1978

Number of shared co-authors 1

Martine F Roussel

St. Jude Children's Research Hospital

Career Start Year 1977

Number of shared co-authors 1

Webster K Cavenee

Ludwig Institute for Cancer Research, University of California San Diego

Career Start Year 1977

Number of shared co-authors 1

Frank McCormick

Frederick National Laboratory for Cancer Research

Career Start Year 1975

Number of shared co-authors 1

Owen N Witte

University of California los angeles

Career Start Year 1972

Number of shared co-authors 0

Tony Hunter

Salk Institute for Biological Studies

Career Start Year 1968

Number of shared co-authors 0

Charles J Sherr

St. Jude Children's Research Hospital

Career Start Year 1968

Number of shared co-authors 0

Marion M Nau

Center for Cancer Research, National Cancer Institute

Career Start Year 1967

Number of shared co-authors 0

Arnold J Levine

Simons Center for Systems Biology, Institute for Advanced Study

Career Start Year 1967

Number of shared co-authors 0

J. Carl Barrett

Oncology R&D

Career Start Year 1966

Number of shared co-authors 0

row(s) 1 - 30 of 30

Matthew N McCall

Co-authored papers 6

Linda Z Penn

University of Toronto

Co-authored papers 4

Mark Noble

University of Rochester Medical Center

Co-authored papers 4

Veronica Clavijo Jordan

Harvard Medical School

Co-authored papers 3

Damian R Wren

Frimley Health NHS Foundation Trust

Co-authored papers 2

Oliver B??gler

American Association for Cancer Research, Henry Ford Hospital, Ludwig Institute for Cancer Research, National Cancer Institute, Salk Institute for Biological Studies, University of Cambridge, University of Texas MD Anderson Cancer Center, Virginia Commonwealth University

Co-authored papers 2

Susan C Barnett

University of Glasgow, University Place

Co-authored papers 2

Stephen Dalton

Center for Molecular Medicine, University of Georgia

Co-authored papers 1

Nabeel Bardeesy

Massachusetts General Hospital

Co-authored papers 1

Andreas von Deimling

Co-authored papers 1